Anixa Biosciences, Inc. (ANIX) Analysts See $-0.15 EPS

November 8, 2018 - By Ann Prendergast

Analysts expect Anixa Biosciences, Inc. (NASDAQ:ANIX) to report $-0.15 EPS on December, 7.After having $-0.30 EPS previously, Anixa Biosciences, Inc.’s analysts see -50.00 % EPS growth. The stock decreased 2.78% or $0.11 during the last trading session, reaching $3.84. About 107,310 shares traded. Anixa Biosciences, Inc. (NASDAQ:ANIX) has 0.00% since November 9, 2017 and is . It has underperformed by 15.62% the S&P500.

Anixa Biosciences, Inc. develops, acquires, and licenses emerging technologies in the areas of biotechnology. The company has market cap of $71.79 million. The firm develops Cchek, a platform for non-invasive blood tests for the early detection of various cancers, including breast, lung, colon, melanoma, ovarian, liver, thyroid, pancreatic, appendiceal, uterine, osteosarcoma, leiomyosarcoma, liposarcoma, vulvar, and prostate cancer. It currently has negative earnings. It also develops immuno-therapy drugs for the treatment of cancer.

More notable recent Anixa Biosciences, Inc. (NASDAQ:ANIX) news were published by: Streetinsider.com which released: “Anixa Biosciences (ANIX) Announces Scheduling of Pre-Sub Meeting with FDA for its Cchek Cancer” on October 24, 2018, also Benzinga.com with their article: “74 Biggest Movers From Friday” published on November 05, 2018, Streetinsider.com published: “Anixa Biosciences (ANIX), Moffitt Cancer Center Report Completion of Pre-IND Meeting with FDA for CAR-T Therapy” on October 22, 2018. More interesting news about Anixa Biosciences, Inc. (NASDAQ:ANIX) were released by: Benzinga.com and their article: “58 Biggest Movers From Yesterday” published on October 23, 2018 as well as Prnewswire.com‘s news article titled: “Anixa Biosciences Releases Data Presented at AACR Artificial Intelligence Conference” with publication date: October 17, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.